What is Leerink Partnrs' Forecast for SLDB Q1 Earnings?

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for Solid Biosciences in a research report issued to clients and investors on Monday, April 21st. Leerink Partnrs analyst J. Schwartz anticipates that the company will earn ($0.41) per share for the quarter. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. Leerink Partnrs also issued estimates for Solid Biosciences' Q2 2025 earnings at ($0.41) EPS, Q3 2025 earnings at ($0.42) EPS, Q4 2025 earnings at ($0.42) EPS and FY2026 earnings at ($1.94) EPS.

SLDB has been the subject of a number of other reports. JPMorgan Chase & Co. dropped their price target on Solid Biosciences from $12.00 to $11.00 and set an "overweight" rating for the company in a research report on Thursday, March 13th. HC Wainwright raised their target price on Solid Biosciences from $16.00 to $20.00 and gave the stock a "buy" rating in a research note on Monday, March 10th. Truist Financial started coverage on Solid Biosciences in a report on Wednesday, January 8th. They issued a "buy" rating and a $16.00 price objective on the stock. Finally, Chardan Capital reaffirmed a "buy" rating and set a $16.00 target price on shares of Solid Biosciences in a research note on Friday, March 7th. Eight investment analysts have rated the stock with a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat.com, Solid Biosciences currently has an average rating of "Buy" and a consensus price target of $15.67.

Solid Biosciences Stock Down 2.9 %

Shares of Solid Biosciences stock traded down $0.10 during trading hours on Thursday, reaching $3.14. 305,626 shares of the company's stock were exchanged, compared to its average volume of 933,050. The company has a market capitalization of $242.94 million, a P/E ratio of -1.03 and a beta of 2.07. Solid Biosciences has a 1 year low of $2.45 and a 1 year high of $10.99. The business has a fifty day moving average of $4.18 and a two-hundred day moving average of $4.48.

Institutional Trading of Solid Biosciences

Hedge funds and other institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP boosted its stake in shares of Solid Biosciences by 4.0% during the fourth quarter. Wellington Management Group LLP now owns 124,551 shares of the company's stock valued at $498,000 after acquiring an additional 4,747 shares during the last quarter. Vestal Point Capital LP raised its holdings in Solid Biosciences by 1.8% in the 4th quarter. Vestal Point Capital LP now owns 2,850,000 shares of the company's stock valued at $11,400,000 after acquiring an additional 50,000 shares during the last quarter. Redmile Group LLC purchased a new stake in shares of Solid Biosciences in the fourth quarter valued at $2,461,000. D. E. Shaw & Co. Inc. acquired a new position in Solid Biosciences in the fourth quarter valued at $208,000. Finally, Corton Capital Inc. purchased a new position in Solid Biosciences during the fourth quarter worth about $41,000. Hedge funds and other institutional investors own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.